Trial intelligence / Profile preview

Tesetaxel plus reduced-dose capecitabine versus capecitabine alone in previously taxane-treated HR-positive/HER2-negative advanced breast cancer

2017-002961-23Phase 3Terminated

Sponsor

Odonate Therapeutics

Start

Nov 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1